Latest


News headlines

  •   Mon, Apr 17 2006 12:00:00 AM

Business Standard

Bangalore, Apr 18: Kiran Mazumdar-Shaw, chairman and managing director, Biocon, speaking to reporters after the inauguration of Biocon Biopharmaceuticals' facility here on Monday said that the clinical trials were conducted at Manipal Hospital in Bangalore and KMC hospitals in Mangalore and Manipal.

"It is now for the regulators to look at the data and approve it. We are in the process of compiling the data and filing it before the Drug Controller General of India (DGCI) for approval. We will be filing it next month," she added.

BIOMAb EGFR is engineered to specifically target and block the epidermal growth factor receptor.

  

Top Stories


Leave a Comment

Title: News headlines



You have 2000 characters left.

Disclaimer:

Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. Daijiworld.com will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will Daijiworld.com be held responsible.

You might also like